OncoMatch/Clinical Trials/NCT06617481

PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence

Is NCT06617481 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies 18F-rhPSMA-7.3 (Posluma) for prostate cancer (post prostatectomy).

Phase 2RecruitingAdventHealthNCT06617481Data as of May 2026

Treatment: 18F-rhPSMA-7.3 (Posluma) — Flotufolastat F-18, sold under the brand name Posluma, is a radioactive diagnostic agent for use with positron emission tomography (PET) imaging for prostate cancer. The research is being done to study the capability of 18F-rhPSMA-7.3 (flotufolastat F-18) PET scan to detect prostate cancer when there are very low levels of Prostate-Specific Antigen (PSA) following previous radical prostatectomy surgery.

Check if I qualify

Extracted eligibility criteria

Cancer type

Prostate Cancer

Prior therapy

Must have received: radical prostatectomy — curative intent

prior curative intent radical prostatectomy

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

AdventHealth · Orlando, Florida

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify